June 21, 2017
Video
Arjun Balar, MD, assistant professor, Department of Medicine, and director, Genitourinary Medical Oncology Program, NYU Langone Medical Center, discusses biomarker findings and mature clinical results from KEYNOTE-052, which explored first-line pembrolizumab (Keytruda) in cisplatin-ineligible advanced urothelial carcinoma.
May 22, 2017
Video
Arjun Balar, MD, assistant professor, Department of Medicine, and director, Genitourinary Medical Oncology Program, NYU Langone Medical Center, discussed results of the KEYNOTE-052 study of pembrolizumab as a first-line therapy for patients with cisplatin-ineligible advanced urothelial cancer.
October 25, 2016
Video
Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the results of a recent first-line study of pembrolizumab in advanced urothelial cancer.
January 23, 2014
Video
Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the future of bladder cancer.
December 03, 2013
Video
Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses new approaches to the management of metastatic bladder cancer.